Compare ACCL & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACCL | PRLD |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.8M | 69.1M |
| IPO Year | 2025 | 2020 |
| Metric | ACCL | PRLD |
|---|---|---|
| Price | $3.10 | $2.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 82.0K | ★ 499.8K |
| Earning Date | 02-20-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.91 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | $4,888,824.00 | ★ $10,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $35.11 | ★ N/A |
| Revenue Growth | 11.91 | ★ 250.00 |
| 52 Week Low | $2.10 | $0.61 |
| 52 Week High | $5.00 | $4.22 |
| Indicator | ACCL | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 60.23 |
| Support Level | N/A | $2.37 |
| Resistance Level | N/A | $3.00 |
| Average True Range (ATR) | 0.00 | 0.28 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 0.00 | 63.64 |
Acco Group Holdings Ltd is a holding company. Through its Operating Subsidiaries, it is a multi-disciplinary, IT-driven corporate service provider with a presence in Hong Kong and Singapore. Under the Accolade brand, it specializes in offering corporate secretarial services and accounting services in Hong Kong, as well as intellectual properties (IP) registration services in Singapore. Leveraging developed IT solutions, It provides comprehensive, reliable and professional support to its clients, enabling them to focus on their core business activities while it manages and handles their corporate compliance needs. Its clientele ranges from individual clients, small and medium-sized enterprises to multinational corporations, reflecting its ability to cater to diverse business needs.
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.